Tempus AI (NASDAQ:TEM) Given Buy Rating at TD Cowen

TD Cowen reaffirmed their buy rating on shares of Tempus AI (NASDAQ:TEM) in a research note issued to investors on Wednesday morning, Marketbeat reports. They currently have a $74.00 target price on the stock, up from their prior target price of $58.00.

TEM has been the subject of several other research reports. Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and raised their price target for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Loop Capital lowered their target price on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research note on Tuesday, January 14th. Bank of America upped their price target on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research report on Friday, December 13th. Piper Sandler reissued a “neutral” rating and issued a $70.00 price objective (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Finally, Needham & Company LLC restated a “buy” rating and set a $56.00 target price on shares of Tempus AI in a research report on Tuesday, January 14th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Tempus AI has an average rating of “Moderate Buy” and an average price target of $58.55.

Tempus AI Stock Up 11.9 %

Shares of TEM opened at $69.18 on Wednesday. The business has a 50-day moving average of $44.32 and a 200-day moving average of $48.73. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI has a 1 year low of $22.89 and a 1 year high of $79.49.

Insider Activity

In other Tempus AI news, major shareholder Bradley A. Keywell sold 395,800 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the completion of the sale, the insider now directly owns 16,164,449 shares of the company’s stock, valued at approximately $694,263,084.55. The trade was a 2.39 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Eric P. Lefkofsky sold 476,209 shares of the firm’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $49.84, for a total value of $23,734,256.56. Following the completion of the transaction, the chief executive officer now owns 6,502,643 shares in the company, valued at $324,091,727.12. This represents a 6.82 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 2,038,072 shares of company stock worth $89,469,375 over the last quarter.

Institutional Investors Weigh In On Tempus AI

Institutional investors have recently bought and sold shares of the stock. Kovitz Investment Group Partners LLC purchased a new position in Tempus AI during the 3rd quarter worth $1,367,000. China Universal Asset Management Co. Ltd. purchased a new position in Tempus AI during the fourth quarter worth about $1,091,000. Sumitomo Mitsui Trust Group Inc. grew its position in Tempus AI by 1,591.2% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock worth $68,922,000 after purchasing an additional 1,145,698 shares in the last quarter. Captrust Financial Advisors purchased a new stake in Tempus AI in the 3rd quarter valued at about $2,726,000. Finally, Sigma Planning Corp bought a new position in shares of Tempus AI during the 3rd quarter worth approximately $1,323,000. Institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.